________________________________________________________________________________________________________________________
a fast-track designation of their vaccine and get it to market quicker than they would’ ve been able to otherwise. We’ re very proud of that contribution that hVIVO made to getting those RSV vaccines to market, which are now saving the lives of millions of babies and elderly people worldwide.
“ From that success, we’ ve pivoted and started working on the hMPV vaccines, as it comes from the same family of virus. Because hMPV is a pathogen that’ s never had a vaccine efficacious against it before, our challenge model is key as it will enable developers to test new vaccines extremely quickly.”
As hVIVO continues to evolve, its combination of scientific expertise, integrated capabilities, and forward-thinking investment strategy positions the company at the forefront of early-phase clinical development. By accelerating access to high-quality human data and delivering tailored support across the drug development pathway, hVIVO is both helping its clients bring new therapies to market faster and shaping the future of modern clinical research. With hVIVO’ s human challenge models, the opportunities are monumental.
“ We’ ve recently announced that we’ re in the position to conduct the world’ s first Phase Three challenge study, where the only efficacy component will come directly from the study. That’ ll be working on a new and improved vaccine for pertussis( whooping cough), which would be a groundbreaking development to get better efficacy for this very difficult disease – and we have the commercial
84